Latest From Nevakar LLC
Private Company Edition: Polaris is raising up to $400m for its next tech and health care fund, following in the footsteps of several life science investors this year. Also, Nevakar raises $50m in a product financing agreement and RAPT closes a $37m series C extension.
Sarepta licenses gene therapy candidate from Lacerta, also makes equity investment. Neuren licenses North American rights to rare disease drug trofinetide to Acadia.
Ambrx, Arcus, Cleave Biosciences, InflaRx, MonoSol Rx, Nevakar and Tioma Therapeutics were among firms raising more than $30m in venture funding in July and August. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive review of emerging biopharmaceutical companies that have received venture funding during the past two months.
- Drug Delivery
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- Nevakar LLC
- Senior Management
Navneet Puri, PhD, CEO
Kumaresh Soppimath, PhD, VP, R&D
Vishweshwar Shetty, VP, Commercial Dev.
- Contact Info
Phone: (908) 367-7400
1019 US Hwy. 202-206
Bridgewater, NJ 08807
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.